

institutes and centers. This process produced many modifications and the final proposal presented below. Additional background information can be found here <https://grants.nih.gov/policyproposed-Framework/index.htm>.

Proposed Revised Simplified Review Framework

An Overall Impact Score (scored 1–9) will reflect the overall scientific and technical merit of the application. Reviewers will take into account their assessments of the three factors below and the following additional criteria in determining an Overall Impact Score. Of the three factors, only Factor 1: Importance of the Research and Factor 2: Feasibility and Rigor, will receive individual scores. In the revised framework, Factor 3: Expertise and Resources will not receive an individual score. The additional review criteria below will not receive individual scores but will be considered in arriving at the Overall Impact Score. Two review considerations will be evaluated but have no effect on the Overall Impact Score. Detailed descriptions of the three factors can be found here <https://grants.nih.gov/policyproposed-Framework/reviewer-guidance.htm>.

Factor 1: Importance of the Research (scored 1–9).

Factor 1 is based on the criteria Significance and Innovation.

Factor 2: Feasibility and Rigor (scored 1–9).

Factor 2 is based on the criteria Approach.

Factor 3: Expertise and Resources (rated as “fully capable”, “appropriate” or “additional capability/expertise needed” or “additional resources needed”)

Factor 3 is based on the criteria Investigator and Environment. If “additional expertise/capability needed” or “additional resources needed” is selected, justification must be provided.

Additional Criteria (not scored, but affecting Overall Impact):

- Human Subject Protections
 - Inclusion of Women, Minorities, and Individuals Across the Lifespan
 - Vertebrate Animals
 - Biohazards
 - Resubmission/Renewal/Revisions
- Each of the Additional Criteria except the last will be rated as “Appropriate”, with no comments required, or as “Concerns”, which must be briefly justified. Resubmission/Renewal/Revisions will be given brief written evaluations.

Additional Review Considerations (not scored and having no effect on Overall Impact):

- Authentication of Key Biological and/or Chemical Resources
- Rated as “Appropriate” with no comments required, or as “Concerns”, which must be briefly described.
- Budget and Period of Support
- Rated as “Appropriate”, “Excessive”, or “Inadequate”; the latter two ratings requiring a brief account of concerns.

The additional review considerations, including Foreign Organizations, Select Agents, and Resource Sharing Plans, will no longer be evaluated by peer reviewers.

Restructuring the categorization and scoring of criteria in this way reduces the number of scores reviewers need to provide, and policy considerations reviewers need to take into account when evaluating scientific merit. It focuses reviewers on the two most important judgements about a proposed research project; how important the research is, and how rigorous and feasible the approach is. Evaluation of the investigators and research environment is framed in terms of whether the expertise and resources needed to accomplish the project are available, thus diminishing halo effects—diffuse judgements of investigator or institutional reputation that bias judgements of research importance, rigor, and feasibility.

Submitting a Response

Comments should be submitted electronically to the following web page at: <https://rfi.grants.nih.gov/?s=638509b5409baa49f803e572>.

This RFI is for planning purposes only and should not be construed as a policy, solicitation for applications, or as an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for its use of that information.

Please do not include any proprietary, classified, confidential, or sensitive information in your response. Responses will be compiled and a content analysis will be shared publicly after the close of the comment period. The NIH may use information gathered by this Notice to inform future policy development.

Dated: December 1, 2022.

Tara A. Schwetz,
Acting Principal Deputy Director, National Institutes of Health.

[FR Doc. 2022–26603 Filed 12–6–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Inherited Disease Research Access Committee.

Date: January 6, 2023.

Time: 11:30 a.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 3100, Room 3185, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Barbara J. Thomas, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Suite 3100, Room 3185, Bethesda, MD 20892, (301) 402–8837, barbara.thomas@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS).

Dated: December 2, 2022.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022–26588 Filed 12–6–22; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Cardiovascular and Surgical Devices.

Date: December 16, 2022.

Time: 7:00 a.m. to 8:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Willard Wilson, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, 301-867-5309, willard.wilson@nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS).

Dated: December 2, 2022.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-26587 Filed 12-6-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II

Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required).

Date: January 13, 2023.

Time: 9:00 a.m. to 11:00 a.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room RML 31/31118A, Rockville, MD 20892 (Virtual Meeting).

Contact Person: Dylan Paul Flather, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room RML 31/31118A, Rockville, MD 20852, (406) 802-6209, dylan.flather@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: December 2, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-26612 Filed 12-6-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

[Document Identifier: 0930-0092]

Agency Information Collection Request; 60-Day Public Comment Request; Correction

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services.

ACTION: Notice; correction.

SUMMARY: The Substance Abuse and Mental Health Services Administration published a document in the **Federal Register** on November 22, 2022, concerning request for comments on Confidentiality of Substance Use Disorder Patient Records. The document only listed the Department of Health and Human Services in the headings and contained an incorrect Document Identifier and contact for further information or submission of public comments. This document corrects those errors. Comments on the information collect request must be received on or before January 23, 2023.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of November 22, 2022, at 87 FR 71341, in FR Doc. 2022-25343, the following corrections are made:

1. On page 71341, in the second column, in the headings, add

“Substance Abuse and Mental Health Services Administration” following “DEPARTMENT OF HEALTH AND HUMAN SERVICES” and “Document Identifier: OS-0990-New” is corrected to read “Document Identifier: 0930-0092”.

2. On page 71341, in the second column, correct the “ADDRESSES” and “FOR FURTHER INFORMATION CONTACT” captions to read:

ADDRESSES: Submit your comments to Carlos.Graham@hhs.gov or by calling (240) 276-0361.

FOR FURTHER INFORMATION CONTACT: When submitting comments or requesting information, please include the document identifier 0930-0092, and project title for reference, to Carlos Graham, Reports Clearance Officer; email: CarlosGraham@hhs.gov, or call (240) 276-0361.

Carlos Graham,

Reports Clearance Officer.

[FR Doc. 2022-26508 Filed 12-6-22; 8:45 am]

BILLING CODE 4162-20-P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4673-DR; Docket ID FEMA-2022-0001]

Florida; Amendment No. 12 to Notice of a Major Disaster Declaration

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

SUMMARY: This notice amends the notice of a major disaster declaration for the State of Florida (FEMA-4673-DR), dated September 29, 2022, and related determinations.

DATES: This amendment was issued November 10, 2022.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and Recovery, Federal Emergency Management Agency, 500 C Street SW, Washington, DC 20472, (202) 646-2833.

SUPPLEMENTARY INFORMATION: The notice of a major disaster declaration for the State of Florida is hereby amended to include the following area among those areas determined to have been adversely affected by the event declared a major disaster by the President in his declaration of September 29, 2022.

Martin County for debris removal [Category A] and permanent work [Categories C-G] (already designated for emergency protective measures [Category B], including direct